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Abstract 
Introduction 
As key cell cycle regulators, cyclin-dependent kinases 4 and 6 (CDK4/6) in-
teract with cyclin D to hyperphosphorylate retinoblastoma (Rb), releasing 
transcription factors that allow cell proliferation. During oestrogen receptor 
(ER)-positive luminal breast cancer, dysregulation of the cell cycle occurs 
through loss of Rb function, or amplification of cyclin D1 or CDK. Abema-
ciclib, the third small molecule CDK4/6 inhibitor to be developed, blocks 
phosphorylation and prevents cell cycle progression. By targeting the ER 
and cyclin D-CDK4/6 pathways in combination, it is thought that this may 
lead to extensive inhibition of tumour growth and prevent endocrine therapy 
(ET) resistance.  
Methodology  
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer. Quality assessment was conducted to assess 
the risk of bias at the study level based on the EUnetHTA internal validity 
for randomized controlled trials. Furthermore, the magnitude of clinically 
meaningful benefit that can be expected from abemaciclib was evaluated 
based on, the Magnitude of Clinical Benefit Scale developed by the Europe-
an Society for Medical Oncology. 
Results of the MONARCH 3 trial 
In the phase III, MONARCH 3 study, 493 postmenopausal women with 
hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-
negative advanced breast cancer (ABC), without prior systemic treatment for 
advanced disease, were randomised 2:1 to abemaciclib or placebo plus a non-
steroidal aromatase inhibitor until disease progression or unacceptable tox-
icity. At interim analysis, while overall survival (OS) data were not mature, 
there were 32 (9.8%) deaths in the abemaciclib group and 17 (10.3%) in the 
placebo group. At a median follow-up of 17.8 months, median progression-
free survival (PFS) was 14.7 months in the placebo group but had not yet 
been reached in the abemaciclib group. While a consistent PFS benefit was 
observed across subgroups, patients with indicators of poor prognosis, such 
as short treatment-free interval or liver metastases, derived greater benefit 
from abemaciclib than those with longer treatment-free intervals or bone-
only disease. Abemaciclib also increased the overall response rate (ORR) by 
13.7% and the clinical benefit rate by 6.5%. Grade ≥3 adverse events were 
more common in abemaciclib recipients compared to placebo (55.0% versus 
21.7%); notably neutropenia (21.1%), diarrhoea (9.5%), leukopenia (7.6%), 
increased alanine aminotransferase (6.1%), and anaemia (5.8%). 
Conclusion 
Overall, abemaciclib with endocrine therapy substantially reduces the risk 
of disease progression and increases ORR versus ET alone as initial therapy 
for HR-positive, HER2-negative ABC in postmenopausal women. OS and 
quality of life data are needed to confirm patients achieve a clinically rele-
vant benefit over time in the context of increasing toxicity. Biomarker trials 
that track cellular proliferation and evaluate Rb protein and ER activity may 
help to identify which patients benefit most from adding abemaciclib as ini-
tial treatment. As there are no comparative trials, differences in the safety 
profiles of CDK4/6 inhibitors may assist physicians in selecting the most 
appropriate CDK4/6 inhibitor to meet individual patient needs.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1].The Model organis-
es HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is abemaciclib? 
A0022 Who manufactures abemaciclib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has abemaciclib received marketing authorisation? 
Health problem and current use 
A0002 What is breast cancer? 
A0004 What is the natural course of breast cancer? 
A0006 What are the consequences of breast cancerfor the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of breast cancer? 
A0003 What are the known risk factors for breast cancer? 
A0024 
How is breast cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is breast cancer currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of abemaciclib on mortality? 
D0005 
How does abemaciclib affect symptoms and findings (severity, frequency) of breast 
cancer? 
D0006 How does abemaciclib affect progression (or recurrence) of breast cancer? 
D0011 What is the effect of abemaciclib on patients ̕ body functions? 
D0012 What is the effect of abemaciclib on generic health-related quality of life? 
D0013 What is the effect of abemaciclib on disease-specific quality of life? 
Safety 
C0008 How safe is abemaciclib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying abemaciclib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of abemaciclib? 
A0021 What is the reimbursement status of abemaciclib? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Abemaciclib/Verzinio™/LY2835219 
 
B0001: What is abemaciclib? 
As key cell cycle regulators, cyclin-dependent kinases 4 and 6 (CDK4/6) in-
teract with cyclin D1 to hyperphosphorylate retinoblastoma (Rb), causing 
the release of transcription factors that allow cell proliferation. Dysregula-
tion of the cell cycle during cancer may occur through loss of Rb function, or 
amplification of cyclin D1 or CDK. Abemaciclib, the third small molecule 
CDK4/6 inhibitor to be developed, blocks phosphorylation and prevents cell 
cycle progression.  
Abemaciclib is administered as a 150 mg oral tablet taken twice daily with a 
nonsteroidal aromatase inhibitor (NSAI), either 1 mg of anastrozole or 2.5 
mg of letrozole taken once daily. Treatment is continued in 28-day cycles 
until disease progression or unacceptable toxicity [2].  
Patients require complete blood counts (CBCs) and liver function tests 
(LFTs) prior to starting abemaciclib and periodic monitoring during treat-
ment due to the risks for neutropenia, hepatotoxicity and venous thrombo-
embolism. Dose interruption, reduction (to 100 mg or 50 mg), or discontin-
uation may be required in patients that develop diarrhoea, hepatotoxicity, 
hematologic or other toxicities, or intolerance due to adverse events (AEs). 
Patients should avoid concomitant use of ketoconazole or strong CYP3A in-
ducers, and have their dose reduced when using CYP3A inhibitors [3].  
 
A0022: Who manufactures abemaciclib? 
Eli Lilly and Company 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Abemaciclib is indicated, in combination with a NSAI, as initial therapy 
for postmenopausal women with hormone receptor (HR)-positive, human 
epidermal growth factor receptor 2 (HER2)-negative advanced breast can-
cer (ABC) [2].  
 
 
CDK4/6 inhibitor  
150 mg twice/day  
with a NSAI 
monitor CBC and LFT 
reduce/interrupt 
dose/discontinue for 
safety/tolerability 
postmenopausal women 
with HR-positive, HER2-
negative ABC 
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4 Current regulatory status 
A0020: For which indications has abemaciclib received marketing authorisa-
tion? 
In September 2017, the US Food and Drug Administration (FDA) granted 
approval of abemaciclib as monotherapy for patients with HR-positive, 
HER2-negative ABC with disease progression following endocrine therapy 
(ET) and chemotherapy for metastatic disease; and in combination with ful-
vestrant for patients with HR-positive, HER2-negative ABC with disease 
progression following ET [3, 4]. Approval was based on the results of the 
phase II MONARCH 1 and phase III MONARCH 2 trials [4-6].  
In October 2017, the FDA granted a priority review for abemaciclib in com-
bination with an aromatase inhibitor (AI) as initial endocrine-based therapy 
for the treatment of women with HR-positive, HER2-negative advanced or 
metastatic breast cancer (A/MBC) [4, 7]. The new drug application (NDA) 
was based on interim results of the phase III MONARCH 3 trial [2].  
Regulatory submissions for abemaciclib were completed for Europe and Ja-
pan in the fall of 2017 [4]. Abemaciclib does not currently have marketing 
authorisation in Europe for any indication. However, in February 2018, a 
Marketing Authorisation Application (MAA) for abemaciclib was submitted 
to the European Medicines Agency (EMA) for the treatment of patients with 
HR-positive, HER2-negative locally advanced or metastatic breast cancer 
(MBC) [8].  
 
 
 
5 Burden of disease 
A0002: What is breast cancer? 
Breast cancer is the most common cancer in women worldwide and the lead-
ing cause of cancer death in women. As a heterogeneous malignancy, breast 
cancer is molecularly subtyped as luminal A, luminal B, HER2-enriched, 
basal-like, or claudin-low [9]. Luminal HR-positive, HER2-negative breast 
cancer, characterized by oestrogen receptor (ER) expression in the absence 
of HER2 amplification, accounts for approximately 70% of all breast can-
cers. ETs target this subtype effectively reducing the relative risk of recur-
rence by approximately 40% [10]. However, some patients inevitably devel-
op resistance to ET.  
CDK4/6 are key drivers of cell proliferation in ER-positive luminal breast 
cancer; and cyclin D1 is frequently overexpressed while Rb function may be 
reduced. Approximately 50% of all breast cancers overexpress cyclin D1 and 
the coding region for cyclin D1 (CCDND1) is amplified in 15–20% of cases 
[11]. Low Rb expression occurs in 20% of cases [12] 
 
 
FDA: licensed mono/+ 
fulvestrant for HR-
positive, HER2-negative 
A/MBC in September 
2017 
NDA: + AI as initial 
therapy for HR-positive, 
HER2-negative A/MBC 
in October 2017 
EMA: MMA for HR-
positive, HER2-negative 
A/MBC in February 2018 
HR-positive, HER2-
negative breast cancer 
accounts for 70% of all 
breast cancers 
CDK4/6 drive cell 
proliferation: cyclin D1 
overexpression in 50% 
of all breast cancers; Rb 
function reduced in 
20% of cases 
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A0004: What is the natural course of breast cancer? 
Breast cancer typically arises when epithelial cells lining the milk ducts 
and/or lobules undergo aberrant cell growth due to dysregulation of the cell 
cycle. In the early stages, atypical cells confined to the milk ducts are termed 
stage 0, ductal carcinoma in situ (DCIS). Stage I breast cancer is invasive 
but is restricted to the area where the first abnormal cells arose. Most (70%–
80% of) breast cancers are diagnosed as stage I (localized to one area) or 
stage II (early locally advanced), invasive ductal carcinoma (IDC) or inva-
sive lobular carcinoma (ILC), where abnormal cells have spread beyond the 
ducts or glands into the breast tissue.  
Stage III, locally advanced breast cancer includes tumours larger than five 
centimetres in diameter that involve the skin, underlying muscle, lymph 
nodes or inflammatory breast cancer (IBC). Breast cancer cells commonly 
travel through the lymphatic system and blood stream forming metastatic 
tumours in bone, liver, lungs and brain. Between 5% and 10% of patients are 
diagnosed with stage IV MBC that has spread to distant parts of the body 
and have a five-year survival rate of less than 25% [13, 14]. 
 
A0006: What are the consequences of breast cancer for the society? 
Globally, breast cancer is the most frequently diagnosed malignancy and the 
leading cause of cancer death in women worldwide [15]. Approximately 30% 
of women diagnosed with early stage breast cancer develop advanced or 
MBC despite treatment [13]. Patients may progress or further metastasize, 
causing significant cancer specific morbidity and mortality. In Austria, 
breast cancer is the 19
th
 leading cause of disability adjusted life years and ac-
counts for approximately 28,000 (2.6% of total) years of life lost due to 
premature mortality [16]. Breast cancer resulted in 1,548 deaths with an 
overall mortality of 8.9 per 1000,000 persons; 0.3 per 100,000 men and 16.0 
per 100,000 women (based on the WHO-world population 2011) [17]. 
 
A0023: How many people belong to the target population? 
About 30% of all malignant neoplasm cases in Austria are due to breast can-
cer. It is the most common cause of death due to cancer in females. The age 
standardised incidence rate for the European Standard Population (2015) is 
63.3 per 100,000 persons per year. In 2015, 5,480 persons were newly diag-
nosed with breast cancer in Austria, of whom approximately 98% were wom-
en. Moreover, around 86% of female breast cancer patients and 78% of male 
breast cancer patients (all stages are included) are alive at least five years af-
ter diagnosis [17]. The median age at diagnosis of breast cancer is 62 years 
(range 55 to 64 years) in women [18].  
HR-positive disease accounts for approximately 65% and 80% of breast can-
cers in pre- and postmenopausal women, respectively. Approximately 70% 
of breast cancer patients have HR-positive, HER2-negative; the most com-
mon type of breast cancer. Therefore, about 3,836 of the 5,480 persons diag-
nosed with breast cancer in 2015 in Austria were affected by HR-positive, 
HER2-negative disease. Between 5% and 10% of patients present with MBC 
at diagnosis, and about 30% of people with localized disease will later devel-
op metastases [13, 19].  
 
staged I–IV by 
invasiveness 
metastasize to bone, 
liver, brain, lymph nodes 
5 year survival <25% 
metastasize 
leading cause of cancer 
death in women 
worldwide 
incidence rate based on 
the European Standard 
Population: 63.3 per 
100,000 persons/year 
HR-positive, HER2-
negative most common 
subtype 
 ~3,836 cases in Austria 
in 2015 
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A0005: What are the symptoms and the burden of breast cancer? 
Signs of breast cancer may include a hard, immovable lump in the breast 
with irregular borders. Patients with locally ABC may experience dimpling 
or thickening of the skin, a change in shape or colour, nipple inversion or 
discharge, and pain in the breast or armpit. Patients with MBC may experi-
ence bone pain, fractures, headaches, seizures, swollen lymph nodes, short-
ness of breath or jaundice depending on the organs involved [14, 15].  
 
A0003: What are the known risk factors for breast cancer? 
Risk factors for developing breast cancer include increasing age, female 
gender, a personal or family history of breast cancer, Caucasian race, obesi-
ty, early menarche, nulliparity or older age at first birth, late menopause, 
hormone replacement therapy, increased breast density, alcohol consump-
tion, cigarette smoking and genetic factors. According to data from the Sur-
veillance Epidemiology, and End Results (SEER) database, the probability 
of developing breast cancer in the United States between 2006 and 2008 was 
2.3 (one in 44 women) for women aged 50 to 59 years, 3.5 (one in 29 women) 
for those aged 60 to 69 years (one in 15 women) for women above the age of 
70 years [14, 15].  
 
A0024: How is breast cancer currently diagnosed according to published 
guidelines and in practice? 
A mammogram of both breasts is performed to define tumour size and assess 
whether the contralateral breast is affected. Breast magnetic resonance imag-
ing (MRI) or ultrasound may also be performed to estimate tumour size and 
distinguish a fluid-filled or a solid mass. During a biopsy, a sample of breast 
cells or tissue from the lump is examined to determine the presence of can-
cer cells, and HR or HER2 protein expression. HR status is an important 
factor in planning clinical management. Bone scans, blood tests, x-rays, 
computed tomography (CT) and Positron-emission tomography (PET) scans 
may be conducted to determine whether breast cancer has spread to bone, 
liver, lungs or brain [15, 20].  
 
 
 
6 Current treatment 
A0025: How is breast cancer currently managed according to published 
guidelines and in practice? 
Previously untreated, advanced and MBC that is HR-positive and HER2-
negative is treated using ET and/or chemotherapy and/or surgery and/or ra-
diation therapy and/or targeted therapy [21].  
First-line ET involves: 
 a third generation AI (anastrozole, letrozole, or exemestane) for 
postmenopausal patients; 
main symptoms: breast 
lump, thickening, pain 
main risk factors: 
increasing age, female 
gender, Caucasian race 
diagnostics: 
mammography, biopsy, 
HR status, bone, CT, PET 
scans 
1st-line: ET involving 
tamoxifen with LHRH 
agonists; AIs+/- CDK 
inhibitor 
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 tamoxifen and ovarian suppression with luteinizing hormone-
receptor releasing hormone (LHRH) agonists or tamoxifen alone 
for premenopausal patients; and  
Patients who progress on ET may undergo second-line treatment involving: 
 a non-cross-resistant AI, tamoxifen, the selective oestrogen down 
regulator (SERD) fulvestrant, fulvestrant plus an AI, an AI plus a 
CDK4/6 inhibitor (palbociclib or ribociclib), any ET in combina-
tion with the rampamycin inhibitor everolimus [20, 21].  
If A/MBC can no longer be controlled, treatment to slow tumour growth or 
palliative care to manage cancer symptoms and side effects of therapies can 
be applied [14].  
 
 
 
7 Evidence 
A literature search was conducted on 12 January 2018 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “abemaciclib”, “verzenio”, “breast cancer”, “breast neo-
plasms”, “mamma carcinoma”, and “advanced”. The manufacturer was also 
contacted and submitted no further evidence other than that identified by 
systematic literature search. A manual search identified two FDA regulatory 
documents [3, 7], an EMA marketing authorization application notification 
[8], seven clinical guidance documents [13-15, 20-23], three statistical doc-
uments [16-18], and two cost documents [24, 25]. Ongoing trials information 
was found on www.clinicaltrials.gov.  
Overall, 120 references were identified. Included in this reported are:  
 MONARCH 3, phase III [2] 
 MONARCH 2, phase III [6] 
 MONARCH 1, phase II [5] 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [26]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 5 of the Appendix. 
The external validity of the included trials was assessed using the EU-
netHTA guideline on applicability of evidence in the context of a relative ef-
fectiveness assessment of pharmaceuticals, considering the following ele-
ments: population, intervention, comparator, outcomes and setting [26]. 
To evaluate the magnitude of “clinically meaningful benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [27]. Additionally, an adapted version (due to perceived 
2nd-line: fulvestrant or 
exemestane with 
everolimus 
A/MBC: continue 
treatment or 
palliative care 
systematic literature 
search in 5 databases:  
105 hits 
 
 
manual search: 15 
additional references 
overall: 120 references 
included: 3 studies 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
external validity 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
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limitations) of the ESMO-MCBS was applied [28]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence, amount of eligible pa-
tients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
7.2 Clinical efficacy and safety –  
phase III studies 
MONARCH 3 (NCT02246621) is a multicentre, randomised, placebo-
controlled phase III study involving 493 postmenopausal women with HR-
positive, HER2-negative ABC who had not received prior systemic therapy 
in the advanced setting [2]. The study was designed to evaluate the safety 
and efficacy of abemaciclib in combination with a NSAI compared to place-
bo plus a NSAI, as initial treatment for HR-positive, HER2-negative ad-
vanced breast cancer. Efficacy analyses were based on all randomly assigned 
patients comprising the intent-to-treat (ITT) population. Safety analyses in-
volved 488 patients who received at least one dose of the study drug.  
Eligible women were 18 years or older, with locally tested HR-positive, 
HER2-negative locoregionally recurrent breast cancer not amenable to sur-
gical resection or radiotherapy with curative or palliative intent. Patients 
must have had adequate organ function; an Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤1, measurable disease or non-
measurable bone-only disease defined by Response Evaluation Criteria in 
Solid Tumors (RECIST) version 1.1, and must not have received systemic 
therapy for advanced disease. Neoadjuvant or adjuvant ET was permitted if 
the patient was disease-free more than twelve months after completing ther-
apy. Patients were excluded if they had visceral crisis, lymphangitic spread, 
internal and external 
review  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quality assurance 
method 
MONARCH 3: NSAI ± 
abemaciclib as initial 
therapy for HR-positive, 
HER2-negative ABC  
ITT (n = 493) stratified 
by metastatic site and 
prior neoadjuvant or 
adjuvant ET 
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leptomeningeal carcinomatosis, inflammatory breast cancer, evidence or his-
tory of central nervous system metastases, or prior treatment with everoli-
mus or a CDK4/6 inhibitor.  
Patients were randomised 2:1 to receive abemaciclib (150 mg twice daily) or 
matching placebo plus a NSAI (either 1 mg anastrozole or 2.5 mg letrozole). 
All drugs were administered orally and taken daily during 28-day cycles un-
til disease progression, unacceptable toxicity, death or patient withdrawal. 
Dose interruptions and reductions were allowed for abemaciclib but not ap-
plicable to NSAI. Randomised patients were stratified by metastatic site 
(visceral, bone only, or other) and prior neoadjuvant or adjuvant ET (AI, no 
ET, or other). At interim analysis, after 194 progression-free survival (PFS) 
events (n = 108 [32.9%] for abemaciclib versus n = 86 [52.1%] for placebo), 
the median follow-up was 17.8 months. At the data cut-off, 162 (49.4% of) 
abemaciclib and 64 (38.8% of) placebo patients continued treatment. 
Abemaciclib patients received a median of 16 cycles of therapy versus 15 cy-
cles for placebo recipients. The median relative dose intensity was 86% for 
abemaciclib and 98% for placebo.  
The primary endpoint of investigator-assessed PFS was evaluated from ran-
domisation until objective disease progression or death. Secondary end-
points reported in the article include objective response rate (ORR; percent-
age of patients with best response of complete response [CR] or partial re-
sponse [PR]), duration of response (DOR; time from CR or PR until disease 
progression or death), clinical benefit rate (CBR; percentage of patients with 
best response of CR, PR, or stable disease [SD] ≥6 months), and safety and 
tolerability. Other endpoints not reported in the current analysis include 
overall survival (OS), quality of life (QoL), pharmacokinetics, and bi-
omarker analyses. Tumours were assessed according to RECIST version 1.1 
at baseline, every second cycle during cycles two to 18, every third cycle 
thereafter, and within 14 days of progression. AEs were graded for severity 
according to the National Cancer Institute Common Terminology Criteria 
version (CTCAE) version 4.0. 
The ITT population (n = 493) had a median age of 63 years (range 32–88), 
58.4% were Caucasian, 52.9% had visceral disease, 39.8% presented with de 
novo metastatic breast cancer, 77.5% were progesterone receptor (PR) posi-
tive, and 46.7% had previously received neo-adjuvant or adjuvant ET, in-
cluding 27.4% who received prior AI therapy. Detailed patient characteris-
tics including inclusion- and exclusion criteria can be found in Table 5 and 
study quality is described in Table 6 of the appendix, respectively. Clinical 
efficacy data are presented in Table 1 and AEs are listed in Table 2. 
 
7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of abemaciclib on mortality? 
While OS data were not mature at interim analysis, there were 32 (9.8%) 
deaths in the abemaciclib group and 17 (10.3%) deaths in the placebo group 
(hazard ratio [HR]: 0.97). Regarding deaths occurring either while receiving 
treatment or within 30 days of discontinuation, 11 (34% of) deaths occurred 
in the abemaciclib group (eight due to adverse events [AEs]) versus three 
(1.9%) in the placebo group (two due to AEs). A final OS analysis will be 
conducted after 315 events.  
NSAI ± abemaciclib (150 
mg twice daily), 28-day 
cycle; median 16 cycles 
of abemaciclib vs 15 
cycles of placebo; 
median follow-up 17.8 
months 
primary endpoint: 
investigator-assessed 
PFS 
secondary endpoints: 
ORR, DOR, CBR, and 
safety 
 
OS, QoL, 
pharmacokinetic and 
biomarker analyses 
were not reported in 
this analysis 
ITT: median age  
63 years,  
78% were  
PR-positive,  
47% had previous ET  
OS: not planned for 
interim analysis 
 will be conducted after 
315 events 
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D0006: How does abemaciclib affect progression (or recurrence) of breast 
cancer? 
Interim analysis were performed after 194 PFS events (n = 108 [32.9%] for 
abemaciclib versus n = 86 [52.1%] for placebo), at a median follow-up of 
17.8 months. The primary endpoint, investigator-assessed median PFS, was 
not reached (NR) in the abemaciclib group and was 14.7 months in the pla-
cebo group (HR 0.54, 95% CI 0.41–0.72; p = 0.000021). Compared with pla-
cebo, abemaciclib increased PFS as observed by independent central review 
(ICR) (HR 0.51, 95% CI 0.36–0.72; p = 0.000102). 
While a PFS benefit was demonstrated across all pre-specified subgroups, 
Asians demonstrated a greater benefit than Caucasians (n = 148 Asians, HR 
0.30, 95% CI 0.17–0.52 versus n = 288 Caucasians, HR 0.69, 95% CI 0.48–
0.99). Abemaciclib demonstrated consistent PFS over placebo across sub-
groups related to prognosis and endocrine sensitivity (treatment-free inter-
val, metastatic site); however, greater benefit was observed in patients with a 
short treatment-free interval (NR for abemaciclib vs 9.0 months for placebo) 
or liver metastases, though not a pre-specified subgroup, (15.0 months for 
abemaciclib vs 7.2 months for placebo). Placebo patients with adverse prog-
nostic factors (treatment-free interval <36 months, median PFS, 9.0 months; 
or liver metastases, median PFS, 7.2 months) demonstrated greater progres-
sion than those with good prognostic factors treatment-free interval >36 
months, or bone only disease (median not reached for either group).  
 
D0005: How does abemaciclib affect symptoms and findings (severity, fre-
quency) of breast cancer? 
The ORR in the ITT population was 48.2% (95% CI 42.8–53.6%, n = 328) in 
the abemaciclib group and 34.5% (95% CI 27.3–41.8%, n = 165) in the pla-
cebo group (odds ratio [OR] 1.8, 95% CI 1.3–2.3; p = 0.002). Clinical benefit 
was achieved in 78% (95% CI 73.6–82.5%) of abemaciclib patients versus 
71.5% (95% CI 64.6–78.4%) of placebo recipients. Of the responders, 101 
(63.9% of) abemaciclib recipients and 34 (59.6% of) placebo recipients con-
tinued treatment at interim analysis. The ORR in patients with measurable 
disease was 59.2% (95% CI 53.3–65.1%) in abemaciclib recipients and 43.8% 
(95% CI 35.3%–52.4%) in placebo recipients (OR 1.9, 95% CI 1.4–2.5; p = 
0.004). The median DOR was NR for the abemaciclib group and was 14.1 
months in placebo group.  
 
D0011: What is the effect of abemaciclib on patients̕ body functions? 
According to central laboratory analysis, abemaciclib may cause increased 
serum creatinine, increased alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), decreased white blood cells, neutrophils, and lym-
phocytes, and anaemia.  
 
D0012: What is the effect of abemaciclib on generic health-related quality of 
life? 
No evidence was reported regarding the effect of abemaciclib on generic 
health-related QoL 
 
median investigator-
assessed PFS: NR for 
abemaciclib vs 14.7 
months for placebo 
greater median PFS: 
Asians, treatment-free 
interval <36 months, 
and liver metastases  
ORR ITT:  
abemaciclib: 48.2% 
placebo: 34.5% 
DOR:  
abemaciclib: NR 
placebo: 14.1 months 
increased creatinine, 
ALT & AST, leukopenia, 
neutropenia, 
lymphocytopenia, & 
anaemia 
generic health-related 
QoL: no evidence 
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D0013: What is the effect of abemaciclib on disease-specific quality of life? 
No evidence was reported regarding the effect of abemaciclib on disease-
specific QoL.  
 
 
 
Table 1: Efficacy results of MONARCH 3 [2] 
Descriptive statistics 
and estimate varia-
bility 
Treatment group Abemaciclib + NSAI Placebo + NSAI 
Number of subjects 328 165 
Interim analysis (17 months) 
194 PFS events, n (%) 
 
108 (32.9) 
 
86 (52.1) 
ICR-assessed median PFS, months 
Investigator-assessed median PFS, months 
  PFS, months, TFI<36 months 
  PFS, months, TFI>36 months 
  PFS, months, with BOD 
  PFS, months, without BOD 
  PFS, months, with liver metastasis 
  PFS, months, without liver metastases 
NR 
NR 
NR (n = 42) 
NR (n = 94) 
NR (n = 70) 
NR (n = 258) 
15.0 (n = 48) 
NR (n = 280) 
19.2 
14.7 
9.0 (n = 32) 
NR (n = 40) 
NR (n = 39) 
11.7 (n = 126) 
7.2 (n = 30) 
15.4 (n = 135) 
Best overall response, % (CI) 
  CR 
  PR 
  SD 
  ≥6 months 
  PD 
  NE 
 
1.5 (0.2–2.9) 
46.6 (41.2–52.0) 
40.5 (35.2–45.9) 
29.9 (24.9–34.8) 
4.3 (2.1–6.5) 
7.0 (4.2–9.8) 
 
0.0 (NA) 
34.5 (27.3–41.8) 
52.1 (44.5–59.7) 
37.0 (29.6–44.3) 
7.3 (3.3–11.2) 
6.1 (2.4–9.7) 
ORR, % (95% CI), all patients 
ORR, % (CI), measurable disease 
48.2 (42.8–53.6) 
59.2 (53.3–65.1) 
34.5 (27.3–41.8) 
43.8 (35.3–52.4) 
CBR, % (95%) all patients with CR, PR or 
SD ≥6 months 
CBR, % (95%) measurable disease with 
CR, PR or SD ≥6 months 
 
78.0 (73.6–82.5) 
 
79.4 (74.5–84.3) 
 
71.5 (64.6–78.4) 
 
69.2 (61.3–77.2) 
DOR, months NR 14.1 
Median OS, months NA NA 
QoL NA NA 
Effect estimate per 
comparison 
 
Comparison groups 
Abemaciclib + NSAI ver-
sus 
Placebo + NSAI 
ICR-assessed PFS 
(primary endpoint) 
HR 0.51 
95% CI 0.36–0.72 
Log-rank test p-value 0.000102 
Investigator-assessed PFS  
(primary endpoint) 
HR 0.54 
95% CI 0.41–0.72 
Log-rank test p-value 0.000021 
Investigator-assessed PFS 
(subgroup analysis) 
HR Caucasian versus 
HR Asian 
0.69 versus 
0.30 
95% CI Caucasian ver-
sus 
95% CI Asian 
0.48–0.99 versus 
0.17–0.52 
Log-rank test p-value NA 
ORR, all patients OR 1.8 
95% CI 1.3–2.3 
Log-rank test p-value 0.002 
 
disease-specific QoL: no 
evidence 
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 ORR, measureable disease OR 1.9 
95% CI 1.4–2.5 
Log-rank test p-value 0.004 
CBR, all patients with CR, PR or SD ≥6 
months 
OR 1.4 
95% CI 1.0–2.0 
Log-rank test p-value 0.101 
CBR, measurable disease, patients with CR, 
PR or SD ≥6 months 
OR 1.7 
95% CI 1.2–2.5 
Log-rank test p-value 0.024 
Abbreviations: BOD = bone-only disease; CBR = clinical benefit rate; CR = complete response; DOR = duration of response; ICR = 
independent central review; NA = not applicable; NE = not evaluable; NSAI = non-steroidal aromatase inhibitor; NR = not reached; 
PD = progressive disease; PFS = progression-free survival; PR = partial response; OR = odds ratio; ORR = objective response rate; OS 
= overall survival; SD = stable disease; TFI = treatment-free interval 
 
 
7.2.2 Safety 
 
C0008: How safe is abemaciclib in relation to the comparator(s)? 
The most frequent investigator-assessed AEs reported in the abemaciclib 
group of the safety population (n = 327 abemaciclib) were diarrhoea, neu-
tropenia, fatigue, infections, and nausea. Grade ≥3 AEs were observed in 
180 (55.0% of) abemaciclib patients and 35 (21.8 % of) placebo patients. The 
most common AEs of grade ≥3 severity in the abemaciclib group were neu-
tropenia (21.1%), diarrhoea (9.5%), leukopenia (7.6%), increased ALT 
(6.1%), anaemia (5.8%) and infections (4.9%).  
Diarrhoea was predominantly of grade 1 (44.6%) or 2 (27.2%) for abema-
ciclib recipients versus 21.7% and 6.8%, respectively for placebo recipients. 
In the abemaciclib group, the median onset was 8.0 days with a median du-
ration of 10.5 days (grade 2) and 8.0 days (grade 3). While most patients 
(76.3%) who experienced diarrhoea did not undergo treatment modification, 
73.3% reported using antidiarrhoeal therapy.  
Neutropenia was reported in 41.3% abemaciclib recipients. Once decreased, 
typically by cycle 2, neutrophil count remained stable and was reversible fol-
lowing discontinuation of abemaciclib. Infections occurred more frequently 
in the abemaciclib group (39.1%) compared to placebo (28.6%); predomi-
nantly of grades 1 and 2 (33.3% for abemaciclib versus 25.5% for placebo). 
Venous thromboembolic events occurred in 16 (4.9% of) abemaciclib recipi-
ents versus one (0.6% of) placebo recipient.  
Serious adverse events (SAEs) were more common in the abemaciclib group 
(27.5%) than in the placebo group (14.9%); the most frequent were lung in-
fections (2.8% versus 0%, respectively). During therapy or within 30 days of 
discontinuation, eleven (3.4%) deaths occurred in the abemaciclib group 
versus three (1.9%) in the placebo group. Death due to AEs occurred in 
eight (2.4%) abemaciclib patients and two (1.2%) placebo patients. Of the 
eight AE-related deaths in the abemaciclib group three were due to lung in-
fection, two embolism, one cerebral ischemia, one pneumonitis and one res-
piratory failure.  
common grade ≥3 AEs: 
neutropenia, diarrhoea, 
leukopenia, increased 
ALT, anaemia, and 
infections 
diarrhoea: median onset 
8 days, duration 8-10.5 
days; 73% used 
antidiarrhoeals 
neutropenia: 45%, 
reversible following 
discontinuation 
AE-related deaths:  
abemaciclib: 2.4% 
placebo: 1.2% 
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C0002: Are the harms related to dosage or frequency of applying 
abemaciclib? 
Abemaciclib dose reductions due to AEs occurred in 142 (43.4% of) patients 
versus ten (6.2% of) patients receiving placebo. AE-related dosage 
interruptions were reported in 184 (56.3% of) abemaciclib recipients versus 
31 (19.3% of) placebo recipients. A total of 64 (19.6%) of the abemaciclib 
group and four (2.5%) of the placebo group discontinued treatment due to 
AEs. The most frequent cause of treatment discontinuation was disease 
progression for 91 (27.7%) of abemaciclib recipients versus 86 (52.1%) of 
placebo recipients. Approximately 2.3% of the abemaciclib group 
discontinued use as a result of diarrhoea.  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of abemaciclib? 
Study participants had a median age of 63 years, adequate organ function 
and an ECOG performance status of ≤1. While PFS benefit was observed 
across age subgroups (<65 years versus ≥65 years), the safety and effective-
ness of abemaciclib have not been established in pediatric patients. While 
no dosage adjustment is necessary for patients with mild or moderate renal 
impairment (CLcr ≥30–89 mL/min), the pharmacokinetics of abemaciclib 
in patients with severe renal impairment, end stage renal disease, or patients 
on dialysis is unknown. Patients with severe hepatic impairment may be re-
quired to reduce the dosing frequency as the liver metabolizes abemaciclib.  
Abemaciclib may cause foetal harm and adverse reaction in breastfed in-
fants, females are advised to use effective contraception and not to breast 
feed for at least three weeks following the last dose of abemaciclib [3].  
dose interruptions: 
abemaciclib: 56.3% 
placebo: 19.3% 
 
discontinued due to 
progression: 
abemaciclib: 27.7% 
placebo: 52.1% 
susceptibles: reduce 
dose frequency in 
patients with hepatic 
impairment 
abemaciclib may cause 
foetal harm 
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Table 2: Most frequent adverse events of MONARCH 3 [2] 
Adverse Event (according  
to CTCAE version 4.0) 
Abemaciclib + NSAI 
(n = 327) 
Placebo + NSAI 
(n = 161) 
15% in either Arm 
Any Grade 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Any Grade  
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Any AE 322 (98.5) 159 (48.6) 21 (6.4) 145 (90.1) 32 (19.9) 3 (1.9) 
Diarrhea 266 (81.3) 31 (9.5) 0 (0.0) 48 (29.8) 2 (1.2) 0 (0.0) 
Neutropenia 135 (41.3) 64 (19.6) 5 (1.5) 3 (1.9) 1 (0.6) 1 (0.6) 
Fatigue 131 (40.1) 6 (1.8) — 51 (31.7) 0 (0.0) — 
Infections and infestations 128 (39.1) 13 (4.0) 3 (0.9) 46 (28.6) 4 (2.5) 1 (0.6) 
Nausea 126 (38.5) 3 (0.9) — 32 (19.9) 2 (1.2) — 
Abdominal pain 95 (29.1) 4 (1.2) — 19 (11.8) 2 (1.2) — 
Anaemia 93 (28.4) 19 (5.8)  0 (0.0) 8 (5.0) 2 (1.2) 0 (0.0) 
Vomiting  93 (28.4) 4 (1.2) 0 (0.0) 19 (11.8) 3 (1.9) 0 (0.0) 
Alopecia 87 (26.6) — — 17 (10.6) — — 
Decreased appetite 80 (24.5) 4 (1.2) 0 (0.0) 15 (9.3) 1 (0.6) 0 (0.0) 
Leukopenia 68 (20.8) 24 (7.3) 1 (0.3) 4 (2.5) 0 (0.0) 1 (0.6) 
Increased blood creatinine 62 (19.0) 7 (2.1) 0 (0.0) 6 (3.7) 0 (0.0) 0 (0.0) 
Constipation 52 (15.9) 2 (0.6) 0 (0.0) 20 (12.4) 0(0.0) 0 (0.0) 
Increased ALT 51 (15.6) 19 (5.8) 1 (0.3) 11 (6.8) 3 (1.9) 0 (0.0) 
Headache 51 (15.6) 2 (0.6) — 24 (14.9) 0 (0.0) — 
Decreased lymphocytes 165 (52.7) 23 (7.3) 2 (0.6) 40 (25.6) 3 (1.9) 0 (0.0) 
Increased AST 115 (36.7) 12 (3.8) 0 (0.0) 26 (23.2) 1 (0.6) 0 (0.0) 
Abbreviations: AE = adverse event; CTCAE = common terminology for cancer adverse events; NSAI = non-steroidal aromatase 
inhibitor 
 
 
7.3 Clinical effectiveness and safety – further studies 
MONARCH 2 (NCT02107703) is an ongoing multicentre, randomised, dou-
ble-blind, placebo-controlled, phase III study to evaluate abemaciclib in 
combination with fulvestrant for the treatment of HR-positive, HER2-
negative ABC in 667 postmenopausal women whose disease progressed 
while receiving prior ET [6]. Patients were randomly assigned 2:1 to receive 
abemaciclib or placebo (150 mg twice daily) with fulvestrant (500 mg, per 
label) in 28-day cycles until disease progression, death or unacceptable tox-
icity. The primary endpoint was investigator-assessed PFS and secondary 
endpoints included OS, ORR, DOR, CBR, QoL and safety. Clinical response 
was based on investigator-assessment (RECIST v1.1) within 28 days of ran-
domisation, every eight weeks the first year, every 12 weeks thereafter, and 
within two weeks of clinical progression. AEs were evaluated at each patient 
visit until follow-up and graded according to CTCAE v4.0.  
MONARCH 2: 
fulvestrant ± 
abemaciclib for HR-
positive, HER2-negative 
ABC with progression on 
prior ET 
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At a median follow-up of 19.5 months, the primary endpoint median PFS 
was 16.4 months in abemaciclib recipients versus 9.3 months in placebo re-
cipients (HR 0.55, 95% CI 0.45-0.68; p < 0.001). A benefit in PFS was ob-
served across all patient subgroups and consistent with those obtained 
through ICR (HR 0.46, 95% CI 0.36–0.58; p < 0.001). OS data were not ma-
ture at primary analysis for PFS. The ORR in the ITT population was 35.2% 
(95% CI 30.8–39.6%) in the abemaciclib group versus 16.1% (95% CI 11.3–
21.0%) in the placebo group (p < 0.001); including 14 CRs (3.1%) in the 
abemaciclib group and one CR (0.4%) in the placebo group. The median 
DOR was NR in the abemaciclib group with 90 responders (57.3%) continu-
ing treatment at interim analysis. Patients with measurable disease achieved 
an ORR of 48.1% (95% CI 42.6–53.6%) in abemaciclib recipients and 21.3% 
(95% CI 15.1–27.6%) for placebo recipients (p < 0.001). The most common 
AEs in the abemaciclib versus placebo groups were diarrhoea (86.4% versus 
24.7%), neutropenia (46.0% versus 4.0%), nausea (45.1% versus 22.9%), and 
fatigue (39.9% versus 26.9%).  
MONARCH 1 (NCT02102490) is an ongoing multinational, single-arm, 
open-label, phase II study to evaluate abemaciclib monotherapy for the 
treatment of refractory HR-positive, HER2-negative MBC [5]. All 132 wom-
en in the trial had experienced disease progression during or following prior 
ET, had received one or two chemotherapy regimens for metastatic disease, 
and had received a taxane in any setting. Approximately 90% of patients had 
visceral disease, and 85% had at least two metastatic sites. Patients received 
abemaciclib (200 mg every twelve hours) continuously until disease progres-
sion or unacceptable toxicity. The primary endpoint was investigator-
assessed ORR and secondary endpoints included CBR, PFS, OS and safety. 
Clinical response was based on investigator-assessment (RECIST v1.1) with 
primary analysis 12 months after the last patient entered. AEs were evaluat-
ed at baseline and during the study, and graded according to CTCAE v4.0.  
At the twelve month final analysis, investigator-assessed ORR was 19.7% 
(95% CI 13.3–27.5), the CBR (≥6 months) was 42.4%, median PFS was 6.0 
months, and median OS was 17.7 months. The median time to response was 
3.7 months, and the median DOR was 8.6 months. The most common treat-
ment-related AEs of any grade were diarrhoea, fatigue, and nausea; 7.6% of 
patients discontinued treatment due to AEs.  
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of abemaciclib? 
Currently, there are no price estimates for Europe.  
Abemaciclib cost approximately US $ 10,948 (~ € 8,843) per month, or US $ 
131,376 (~ € 106,1238) per year [24].  
 
 
 
median investigator-
assessed PFS: 16.4 
months for abemaciclib 
vs 9.3 months for 
placebo 
 
ORR:  
abemaciclib: 35.2% 
placebo: 16.1% 
 
common AEs: diarrhoea, 
neutropenia, nausea, 
and fatigue 
MONARCH 1: 
abemaciclib 
monotherapy for 
refractory HR-positive, 
HER2-negative MBC 
with progression during 
prior ET, chemotherapy 
in a metastatic setting 
ORR: 19.7% 
CBR: 42.4% 
median PFS: 6.0 months 
median OS: 17.7 months 
AEs: diarrhoea, fatigue, 
nausea 
cost: no price estimate 
for Europe  
US $ 10,948/month 
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9 Ongoing research 
Several studies are ongoing to investigate abemaciclib as monotherapy or in 
combination with NSAI, selective oestrogen receptor degraders (SERDs), 
chemotherapy or other anti-cancer agents to treat ABC. In February 2018, 
searches of www.clinicaltrials.gov and www.clinicaltrialsregister.eu using 
the search terms “abemaciclib” and “breast cancer” yielded 16 registered 
studies (four phase III, eight phase II, three phase I and an expanded access 
study). Most studies were industry-sponsored or conducted in collaboration 
with industry.  
Selected ongoing phase II and III studies evaluating abemaciclib in combi-
nation with a NSAI or SERD (MONARCH plus), and with tamoxifen or 
loperamide (nextMONARCH 1) for ABC; in combination with 
transtuzumab with or without a SERD (monarcHER) for HER2-positive 
ABC; in combination with a NSAI (neoMONARCH), with or without stand-
ard adjuvant ET for early-stage breast cancer (MonarchE); and as monother-
apy for triple negative breast cancer (TNBC):  
 NCT02763566: MONARCH plus is a phase III, multicentre, ran-
domised, double-blind, placebo-controlled trial to evaluate the effi-
cacy of abemaciclib in combination with NSAI or fulvestrant for the 
treatment of HR-positive, HER2-negative ABC in postmenopausal 
women. Estimated study completion date is January 2020. 
 NCT02747004: nextMONARCH 1 is a phase II, multicentre, ran-
domised, open-label study to investigate the safety and efficacy of 
abemaciclib plus tamoxifen or abemaciclib monotherapy in women 
with previously treated HR-positive, HER2-negative MBC. Esti-
mated study completion date is May 2019.  
 NCT02675231: monarcHER is a phase II, multicentre, randomised, 
open-label study to determine the effectiveness of abemaciclib plus 
trastuzumab with or without fulvestrant versus standard care phy-
sician’s choice chemotherapy plus trastuzumab for women with 
HR-positive, HER2-positive ABC. Estimated study completion date 
is February 2021. 
 NCT02441946: neoMONARCH is a phase II, multicentre, random-
ised, open-label study to investigate the effectiveness of abemaciclib 
in combination with anastrozole compared with abemaciclib alone 
and anastrozole alone in postmenopausal women with HR-positive, 
HER2-negative, early stage BC. Estimated study completion date is 
January 2018. 
 NCT03155997: monarchE is a phase III, multicentre, randomised, 
open-label trial to evaluate the safety and efficacy of abemaciclib 
with standard adjuvant ET versus standard adjuvant ET alone for 
high risk, node positive, early stage, HR-positive, HER2-negative 
BC. Estimated study completion date is June 2027. 
 NCT03130439: is a phase II, open-label study to evaluate the safety 
and effectiveness of abemaciclib monotherapy for Rb-positive 
TNBC. Estimated study completion date is November 2024. 
 
16 registered studies 
4 industry sponsored 
ongoing phase III 
8 phase II 
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In addition, abemaciclib is currently under investigation for non-small cell 
lung cancer (NSCLC), brain metastases secondary to melanoma, or HR-
positive breast cancer, recurrent glioblastoma, liposarcoma, mantle cell 
lymphoma, and pancreatic cancer.  
 
 
 
10 Discussion 
In September 2017, the FDA approved abemaciclib monotherapy for post-
menopausal women with HR-positive, HER2-negative ABC that progressed 
following ET and chemotherapy for metastatic disease; and in combination 
with fulvestrant for HR-positive, HER2-negative ABC patients who progress 
following ET [3, 4]. In October 2017, a NDA for abemaciclib in combination 
with a NSAI as initial therapy for A/MBC was granted priority review [7]. 
Abemaciclib does not currently have market authorisation in Europe for any 
indication. However, in February 2018, a MAA for abemaciclib was submit-
ted to the EMA for the treatment of patients with HR-positive, HER2-
negative locally A/MBC [8].  
The NDA to the FDA regarding the use of abemaciclib with an AI as first-
line therapy for ABC is based on results of an interim analysis of a phase III 
study [2]. MONARCH 3, a double-blind, randomised trial, compared the 
safety and efficacy of abemaciclib (150 mg twice daily) or placebo plus a 
NSAI for HR-positive, HER2-negative ABC in 493 postmenopausal women 
without prior systemic therapy for advanced disease. At a median follow-up 
of 17.8 months, the investigator-assessed median PFS was 14.7 months in 
the placebo group but had not yet been reached in the abemaciclib group. 
Consistent with PFS observed by ICR, abemaciclib reduced the risk of dis-
ease progression (DP) by 46%, with consistent PFS benefit across sub-
groups. However, patients with indicators of poor prognosis such as a short 
treatment-free interval or liver metastases derived greater benefit from the 
addition of abemaciclib than patients with a longer treatment-free interval 
or bone-only disease. In the ITT population, the ORRs and CBRs were 
48.2% and 78% in abemaciclib recipients versus 34.5% and 71.5% in placebo 
recipients, respectively. The median DOR was 14.1 months in the placebo 
group but had not yet been reached in the abemaciclib group. OS data were 
not mature at the time of interim analysis for PFS; however, 32 (9.8%) 
deaths occurred in the abemaciclib group and 17 (10.3%) in the placebo 
group.  
The most frequently reported AEs in abemaciclib recipients were diarrhoea, 
neutropenia, fatigue, infections and nausea. Grade ≥3 AEs were more com-
mon in the abemaciclib group compared to placebo (55.0% versus 21.7%); 
notably neutropenia (21.1%), diarrhoea (9.5%), leukopenia (7.6%), in-
creased ALT (6.1%), anaemia (5.8%), and infections (4.9%). While the 
76.3% of patients that experienced diarrhoea did not undergo treatment 
modification, 73.3% used antidiarrhoeals. The neutropenia noted in 41.3% 
of abemaciclib recipients was reversible upon discontinuation of therapy. 
AE-related dose interruptions and discontinuations occurred more frequent-
ly in abemaciclib users compared to placebo (56.3% and 19.6% for abema-
ciclib versus 19.3% and 2.5%, respectively, for placebo). Disease progression 
FDA: licensed mono/+ 
fulvestrant for HR-
positive, HER2-negative 
A/MBC; NDA: + NSAI 
 
EMA: MAA submitted 
for HR-positive, HER2-
negative A/MBC 
MONARCH 3: 
abemaciclib increased 
PFS, ORR versus placebo 
at 17.8 months 
 
abemaciclib reduced risk 
of progression by 46%; 
PFS benefit across 
subgroups; poor 
prognosis derive 
greatest benefit 
 
median DOR: 
abemaciclib: NR 
placebo: 14.1 months 
 
 
immature OS 
grade ≥3 AEs: 
neutropenia, diarrhoea, 
leukopenia, increased 
ALT, anaemia, infections 
 
8 deaths due to lung 
infections, embolisms, 
cerebral ischemia, 
pneumonitis and 
respiratory failure 
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was the most frequent cause of discontinuation for 27.7% of abemaciclib re-
cipients and 52.1% of placebo recipients. AE-related deaths were more 
common in the abemaciclib group compared to placebo (3.4% versus 1.9%); 
attributed to lung infections, embolisms, cerebral ischemia, pneumonitis 
and respiratory failure.  
Results of the MONARCH 3 study hold some limitations. While PFS, ORR, 
DOR and discontinuation data are useful outcomes for evaluation in clinical 
trials, follow-up is insufficient to evaluate OS and long-term safety. No evi-
dence was reported regarding the effect of abemaciclib on generic or disease-
specific QoL. Mature OS data and QoL measures are needed to ensure pa-
tients achieve a clinically relevant benefit over time in the context of in-
creased toxicity. While patients with indicators of poor prognosis derived 
greater benefit from the addition of abemaciclib than patients with better 
prognosis, biomarker analyses were not reported in this analysis. It is im-
portant to identify which patients may benefit most from adding abema-
ciclib as initial treatment versus treatment following progression on ET. Bi-
omarkers that track cellular proliferation and those that evaluate Rb protein 
and ER activity may prove useful in this regard [29, 30]. Biomarker trials 
may help to identify patients for whom CDK4/6 inhibition is cost-effective 
[11]. 
The overall generalizability of the MONARCH 3 results may be limited in 
that study participants had good performance status (ECOG 0–1), with ade-
quate organ function, without having received prior ET for MBC; however, 
the clinical effectiveness of abemaciclib may differ in patients with greater 
comorbidity, reduced functional reserve, gastrointestinal disorders, and 
those with moderate to severe renal or hepatic impairment.  
The clinical efficacy and safety data from MONARCH 3 are consistent with 
data from MONARCH 1 and MONARCH 2 in that abemaciclib improves 
PFS and ORR in patients with HR-positive, HER2-negative ABC [2, 5, 6]. 
Abemaciclib was evaluated as initial ET in MONARCH 3, where postmeno-
pausal participants had no prior systemic therapy in the advanced setting, 
while MONARCH 1 and MONARCH 2 participants had disease progression 
on or after prior ET, and had not received chemotherapy or more than one 
line of ET for metastatic disease. While subgroup analysis in MONARCH 3 
suggests Asians may derive greater PFS than Caucasians, no differences in 
PFS were noted by race in MONARCH 2. Similar to safety data from 
MONARCH 1 and MONARCH 2, the most frequent grade ≥3 AEs in 
MONARCH 3 were diarrhoea, neutropenia, and leukopenia. Various ongo-
ing studies are evaluating abemaciclib in combination with a NSAI or SERD 
(MONARCH plus), and with tamoxifen or loperamide (nextMONARCH 1) 
for ABC; in combination with trastuzumab with or without a SERD 
(monarcHER) for HER2-positive ABC; in combination with a NSAI (neo-
MONARCH), with or without standard adjuvant ET for early-stage breast 
cancer (MonarchE); and as monotherapy for TNBC.  
MONARCH 3 is a phase III trial with few methodological limitations. There 
is no risk of bias in the generation of randomisation sequence or allocation 
concealment. Patients were randomly assigned 2:1 to abemaciclib or match-
ing placebo plus a NSAI using an interactive web-based response system. 
Patients, physicians and outcome assessors were blinded as the placebo was 
identical in appearance. Selective outcome reporting is unlikely as all out-
comes were reported as specified in the clinical trial registry. The risk of bi-
MONARCH 3 
limitations: lack of data 
regarding OS, QoL, 
biomarkers predictive of 
response 
generalizability of the 
study population 
differences from 
existing data: indicated 
as initial ET; Asians 
derive greater PFS 
benefit than Caucasians 
low risk of bias: 
randomised, double-
blind, placebo-
controlled, industry 
funded 
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as may be increased by industry involvement in funding, study design, data 
collection, analysis and interpretation.  
Given the non-curative setting of abemaciclib and the statistically signifi-
cant primary endpoint PFS we applied form 2b of the ESMO-MCBS in or-
der to assess whether abemaciclib satisfies the criteria for a “meaningful 
clinical benefit” (score 4 or 5) [27]. However, since the median PFS was not 
reached in the abemaciclib group no score calculations could be applied. 
Although several studies are ongoing, trials are needed to compare the safety 
and efficacy of abemaciclib with palbociclib and ribociclib, two CDK4/6 in-
hibitors currently approved for the treatment of early and advanced HR-
positive, HER2-negative breast cancer. While all three oral CDK4/6 inhibi-
tors are similar in mechanism of action, abemaciclib shows greater affinity 
for CDK4 than palbociclib and ribociclib. CDK4 plays a greater role than 
CDK6 in breast cancer. Compared to other CDK4/6 inhibitors, abemaciclib  
tases and causes fewer cases of neutropenia [9]. Other differences include 
higher rates of diarrhoea and venous thromboembolism (VTE) with abema-
ciclib and more neutropenia than with palbociclib and ribociclib. Aside 
from existing combinations, it is important to determine whether CDK4/6 
inhibitors in combination with chemotherapy, radiotherapy or immune-
checkpoint inhibitors are also more effective than monotherapy [9].  
The cost of abemaciclib is approximately US $ 10,948 (~ € 8,843) per 
month, or US $ 131,376 (~ € 106,1238) per year [24]. This is in keeping with 
a 21-day supply of ribociclib for € 4,380, or palbociclib for € 3,381 [25]. Cur-
rently, there are no price estimates for abemaciclib in Europe. 
Overall, MONARCH 3 is the first phase III, randomised, placebo-controlled 
trial to demonstrate that abemaciclib with ET substantially reduces the risk 
of disease progression and increases ORR versus ET alone as initial therapy 
for HR-positive, HER2-negative ABC in postmenopausal women. While a 
PFS benefit was observed across subgroups, perhaps not all patients warrant 
combination therapy. Approximately 30% of patients have good prognosis 
for which a CDK4/6 inhibitor could be delayed avoiding untimely toxicity 
and cost [23]. OS and QoL data are needed to confirm patients achieve a 
clinically relevant benefit over time in the context of increasing toxicity. As 
there are no comparative trials, differences in the safety profiles of CDK4/6 
inhibitors may assist physicians in selecting the most appropriate CDK4/6 
inhibitor to meet individual patient needs.  
ESMO-MCBS 
evaluations were not 
applicable due to 
immature PFS data 
evidence needed: 
comparative trials, 
CDK4/6 with 
chemotherapy, 
radiotherapy, or 
immune-checkpoint 
inhibitors vs 
monotherapy; higher 
incidence of VTE 
cost: no price estimate 
for Europe;  
US $ 10,948/month 
MONARCH 3: phase III 
RCT reporting benefit in 
PFS and ORR as initial 
therapy for ABC 
 
patient selection: 30% 
have good prognosis 
and may not warrant 
combination therapy 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [27] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
abemaciclib 
breast 
cancer NC PFS 2b (14.7 months) NR 
0.51 
0.36–0.72 - - 
+33.2% grade 
3–4 AEs x - NA
1 
Original 
ESMO-
MCBS 
abemaciclib breast 
cancer 
NC PFS 2b (14.7 months) NR 0.51 
0.36–0.72 
- - x x - NA1 
Abbreviations: AJ = Adjustments; CI = confidence interval; FM = final adjusted magnitude of clinical benefit grade; HR = hazard ratio; m = months; MG = median gain; NA = not applicable; NC = non-curative; NR = not 
reached; PE = primary endpoint; PFS = progression-free survival; PM = preliminary magnitude of clinical benefit grade; QoL = quality of life 
 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint of interest, 
and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the exact same score 
resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically favours drugs with a higher 
degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and outcomes that lead to an up- or 
downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjustments separately. 
 
                                                             
1
 no score calculations could be applied, since the median progression-free survival was not reached in the abemaciclib group 
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12 Appendix  
Table 4: Administration and dosing and of abemaciclib or placebo plus NSAI [2, 3] 
 Abemaciclib + NSAI Placebo + NSAI 
Administration mode 
Orally, swallow whole with or without 
food, twice daily at approximately the 
same time each day [3].  
Matching placebo [2] 
Description of packaging 
7-day dose package 
14-tablet package of 150 mg, oval, yel-
low tablets debossed with “Lilly” on 
one side and “150” on the other side 
[3] 
Matching placebo [2] 
Total volume contained in packaging for sale 
14-tablet package of 150 mg dose pack 
contains 14 tablets (150 mg per tablet, 
150 mg twice daily) [3] 
Matching placebo [2] 
Dosing 
The recommended starting dose is 150 
mg abemaciclib every 12 hours plus ei-
ther 1 mg anastrozole or 2.5 mg letro-
zole orally once daily for 28 days [2]. 
If a patient vomits or misses a dose, 
the next dose should be taken at its 
scheduled time. Abemaciclib dosage 
may be reduced to 100 mg or 50 mg 
twice daily to manage AEs. Patients 
unable to tolerate 50 mg twice daily 
should discontinue use [3]. 
Matching placebo taken orally every 12 
hours plus either 1 mg anastrozole or 
2.5 mg letrozole orally once daily for 
28 days. [2] 
Median treatment duration 
28-day cycle until disease progression, 
unacceptable toxicity, death or with-
drawal 
Median of 16 cycles [2] 
28-day cycle until disease progression 
or unacceptable toxicity, death or 
withdrawal 
Median of 15 cycles [2] 
Contraindications None [3] None 
Drug interactions 
Avoid concomitant use of ketocona-
zole. Reduce abemaciclib dose with 
concomitant use of other strong 
CYP3A inhibitors. Avoid concomitant 
use of strong CYP3A inducers [3]. 
Matching placebo [2] 
Abbreviations: AE = adverse events; NSAI = nonsteroidal aromatase inhibitors 
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Table 5: Characteristics of the phase III MONARCH 3 trial  
Title: MONARCH 3: Abemaciclib as initial therapy for ABC [2] 
Study identifier NCT02246621, EudraCT 2014-001502-18, Eli Lilly and Company 13Y-MC-JPBM, 15417, MONARCH 3 
Design International (22 countries), multicentre (158 centres), randomized, double-blind, placebo-
controlled, phase III 
Duration of main phase: November 2014-November 2015: 493 patients randomized 
2:1 to receive abemaciclib (n = 328) or placebo (n = 165) 
plus NSAI  
Interim analysis: after 194 PFS events (108 abemaciclib, 86 
placebo); median follow-up: 17.8 months 
Duration of Run-in phase: Not applicable 
Duration of Extension phase: Not applicable 
Hypothesis 
Interventional 
The study was designed to evaluate how effective NSAI plus abemaciclib are in postmenopausal 
women with BC. 
Funding Eli Lilly 
Treatments groups 
 
Abemaciclib + NSAI 
(n = 328 ITT, n = 327 safety) 
Abemaciclib 150 mg orally every 12 h plus either 1 mg anas-
trozole or 2.5 mg letrozole orally once daily for 28 days  
Placebo + NSAI 
(n = 165 ITT, n = 161 safety) 
Placebo orally every 12 hours plus either 1 mg anastrozole 
or 2.5 mg letrozole orally once daily for 28 days 
Endpoints and definitions 
 
Progression-free 
survival 
Primary endpoint 
PFS Time from baseline to measured progressive disease or 
death from any cause (approximately 34 months) 
Overall survival 
Secondary endpoint OS 
Time from baseline to date of death from any cause (ap-
proximately 82 months) 
Duration of re-
sponse 
Secondary end-
point 
DOR 
Time from date of CR or PR to date of objective disease 
progression or death due to any cause (estimated up to 34 
months) 
Disease control rate 
Secondary end-
point 
DCR 
Time from baseline to disease progression (approximately 
34 months) 
Clinical benefit rate  
Secondary end-
point 
CBR 
Time from baseline to disease progression (approximately 
34 months) 
Cancer Quality of 
Life Questionnaire-
Core 30 
Secondary end-
point 
EORTC QLQ-
C30 
Change from baseline to end of study in symptom burden 
on the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire-Core 30 (up to 34 
months) 
Symptom burden 
on the EORTC QLQ-
Breast23 Question-
naire 
Secondary end-
point 
EORTC QLQ-
Breast23  
Change from baseline to end of study in symptom burden 
on the EORTC QLQ-Breast23 Questionnaire (up to 34 
months) 
Health Status on 
the EuroQuol 5-
Dimension 5 Level 
Secondary end-
point 
EuroQuol-5D 
5L 
Change from baseline to end of study in health status on 
the EuroQuol 5-Dimension 5 Level (up to 34 months) 
Objective Response 
Rate 
Secondary end-
point 
ORR 
Time from baseline to disease progression (approximately 
34 months) 
Pharmacokinetics  
Secondary end-
point 
PK 
Volume of distribution of abemaciclib, metabolites and 
NSAI therapy (cycle 1 post dose through cycle 4, approxi-
mately 4 months) 
Database lock Last verified June 2017 
Results and Analysis  
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Title: MONARCH 3: Abemaciclib as initial therapy for ABC [2] 
Study identifier NCT02246621, EudraCT 2014-001502-18, Eli Lilly and Company 13Y-MC-JPBM, 15417, MONARCH 3 
Analysis description Primary Analysis 
ITT: PFS was analysed using a log-rank test stratified by metastatic site and prior neoadjuvant or 
adjuvant endocrine therapy. The study was powered to 80% at one-sided  = 0.025 assuming a HR 
of 0.67 in favour of the abemaciclib arm, with a final analysis at 240 PFS events. A pre-specified in-
terim analysis was planned after 189 events. A positive study at the interim required a HR <0.56 
and a two-sided p<0.0005.  
Stratified tests using the Cochran-Mantel-Haenszel test were performed to compare response rates 
between treatment arms. Hypothesis tests were performed at the two-sided 0.05 level and used 
95% CIs. Exploratory subgroup analyses were performed on subgroups pre-specified in the proto-
col and on subgroups identified in the literature as associated with prognosis and/or sensitivity to 
endocrine therapy. Analysis of AEs was performed in the safety population, defined as all patients 
who received at least one dose of study drug. Statistical analyses were performed using SAS (ver-
sion 9.2 or later). 
Analysis population   
Inclusion 
 Postmenopausal women >18 years with locally 
tested HR+, HER2- locoregionally recurrent breast 
cancer non-amenable to resection or radiation 
therapy with curative intent or metastatic disease 
 Measurable disease defined by RECIST v1.1, or non-
measurable bone-only disease with ECOG PS ≤ 1 
with adequate organ function 
 Have not received systemic therapy for advanced 
disease; ET in the neoadjuvant or adjuvant setting 
was permitted provided the patient was disease-
free >12 months from completion of ET 
 Able to swallow capsules 
 
Exclusion 
 Presence of visceral crisis, lymphangitic spread, or 
leptomeningeal carcinomatosis, inflammatory 
breast cancer, evidence or history of CNS metasta-
ses 
 Prior treatment with everolimus or a CDK 4/6 in-
hibitor 
 Currently receiving or previously received chemo-
therapy or ET for locoregionally recurrent or MBC 
 Prior neoadjuvant ET with a disease-free interval 
>12 months from completion of treatment 
 Initiated bisphosphonates or approved RANK-L 
targeted agents <7 days prior to randomization, or 
had major surgery within 14 days prior to randomi-
zation 
 
Characteristics 
 
Abemaciclib + NSAI 
(n = 328) 
Placebo + NSAI 
(n = 165) 
Total 
(n = 493) 
Median age (range), years 63 (38–87) 63 (32–88) 63 (32–88) 
Race 
   Caucasian 
   Asian 
   Other 
 
186 (56.7) 
103 (31.4) 
11 (3.4) 
 
102 (61.8) 
45 (27.3) 
7 (4.2) 
 
288 (58.4) 
148 (30.0) 
18 (3.7) 
ECOG 
   0 
   1 
 
192 (58.5) 
136 (41.5) 
 
104 (63.0) 
61 (37.0) 
 
296 (60.0) 
197 (40.0) 
Disease setting, N (%)  
   De novo metastatic 
   Metastatic recurrent 
   Locoregionally recurrent 
 
135 (41.2) 
182 (55.5) 
11 (3.4) 
 
61 (37.0) 
99 (60.0) 
5 (3.0) 
 
195 (39.8) 
281 (57.0) 
16 (3.2) 
Progesterone receptor status, N (%)  
   Positive 
   Negative 
 
255 (77.7) 
70 (21.3) 
 
127 (77.0) 
36 (21.8) 
 
382 (77.5) 
106 (21.5) 
Metastatic site, N (%) 
   Visceral  
   Bone only 
   Other 
 
172 (52.4) 
70 (21.3) 
86 (26.2) 
 
89 (53.9) 
39 (23.6) 
37 (22.4) 
 
261 (52.9) 
109 (22.1) 
123 (24.9) 
Prior neoadjuvant or adjuvant chem-
otherapy, N (%) 
   Yes 
   No 
 
 
125 (38.1) 
203 (61.9) 
 
 
66 (40.0) 
99 (60.0) 
 
 
191 (38.7) 
302 (61.3) 
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Title: MONARCH 3: Abemaciclib as initial therapy for ABC [2] 
Study identifier NCT02246621, EudraCT 2014-001502-18, Eli Lilly and Company 13Y-MC-JPBM, 15417, MONARCH 3 
Prior ET, N (%) 
   None 
   AI 
   Other ET 
 
178 (54.3) 
85 (25.9) 
65 (19.8) 
 
85 (51.5) 
50 (30.3) 
30 (18.2) 
 
263 (53.3) 
135 (27.4) 
95 (19.3) 
Treatment-free interval, N (%) 
   <36 months 
   ≥36 months 
   Unknown 
 
42/150 (28.0) 
94/150 (62.7) 
14/150 (9.3) 
 
32/80 (40.0) 
40/80 (50.0) 
8/80 (10.0) 
 
74/230 (32.2) 
134/230 (58.3) 
22/230 (9.6) 
Measurable disease, N (%) 
   Yes 
   No 
 
267 (81.4) 
61 (18.6) 
 
130 (78.8) 
35 (21.2) 
 
397 (80.5) 
96 (19.5) 
N of organ sites, N (%) 
   1 
   2 
   ≥3 
 
96 (29.3) 
76 (23.2) 
154 (47.0) 
 
47 (28.5) 
42 (25.5) 
75 (45.5) 
 
143 (29.0) 
118 (23.9) 
229 (46.5) 
Applicability of evidence 
Population 
The MONARCH 3 trial was conducted in postmenopausal women with HR+, HER2- ABC who had 
no prior systemic therapy in the advanced setting. Study participants had good performance sta-
tus, adequate organ function without having received prior ET for MBC; however, results may dif-
fer in patients with greater comorbidity, reduced functional reserve, and those with moderate to 
severe renal or hepatic impairment.  
Intervention 
The dosage, administration and frequency of cycles used in MONARCH 3 is consistent with the 
dosage, administration and schedule recommended for abemaciclib used in combination with ful-
vestrant for the treatment of women with HR+, HER2- advanced or MBC [3]. Treatment contin-
ued until disease progression, unacceptable toxicity, death or patient withdrawal. Dose interrup-
tions and reductions were permitted as per recommended dose adjustments for the management 
of AEs.  Patients were permitted to discontinue either abemaciclib/placebo or NSAI and continue 
the other drug. 
Comparators 
While a matching placebo was used as comparator for MONARCH 3, two other CDK4/6 inhibitors 
(palbociclib and ribociclib) are currently available and may have formed a suitable comparator. 
Outcomes 
While abemaciclib improved PFS and ORR compared with NSAI alone in MONARCH 3, OS data 
were not mature and QoL was not reported in this analysis.  
Setting 
MONARCH 3 was a multinational trial conducted in 22 countries, approximately 63% of patients 
were Caucasian, 33% were Asian and 4% were of other race.  
Abbreviations: ABC = advanced breast cancer; BC = breast cancer; CBR = clinical benefit rate; CDK = cyclin-dependent kinase; CNS = central 
nervous system; CR = complete response; DCR = disease control rate; DOR = duration of response; ECOG = Eastern Cooperative Oncology 
Group; EORTC = European Organization for Research and Treatment of Cancer; ET = endocrine therapy; HER2- = human epidermal growth 
factor receptor 2-negative; HR = hazard ratio; HR+ = hormone receptor-positive; ITT = intent-to-treat; MBC = metastatic breast cancer; NSAI 
= nonsteroidal aromatase inhibitors; OS = overall survival; PFS = progression free survival; PR = partial response; PS = performance status; 
QoL = quality of life; RANK-L = receptor activator of nuclear factor kappa-B ligand; RECIST = Response Evaluation Criteria in Solid Tumours 
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Table 6: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [26] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: randomised 2:1 abemaciclib versus placebo 
via an interactive web-based response system; stratified by metastatic site (visceral, bone on-
ly, or other) and prior neoadjuvant or adjuvant endocrine therapy (AI, no ET, or other) 
no 
Adequate allocation concealment: participants and investigators could not foresee assign-
ment as the study drug was determined by the centralised interactive web-based response 
system  
no 
Blinding: 
Patient: blind to study drug allocation; centralised randomisation no 
Treating physician: blinded to drug allocation; identical matching placebo no 
Outcome assessment: centralised randomisation and allocation; sensitivi-
ty analysis was planned to assess PFS by full, blinded, ICR no 
Selective outcome reporting unlikely: primary endpoints include investigator-assessed PFS, 
ORR, CR, PR, DOR, CBR, safety and tolerability; other endpoints not included in this analysis 
include OS, QoL, pharmacokinetics and biomarker analyses; as per clinicaltrials.gov 
no 
No other aspects which increase the risk of bias: while all authors were accountable for all as-
pects of the work, industry was involved in funding, study design, study materials, data col-
lection, analysis and interpretation 
yes 
Risk of bias – study level low 
Abbreviations: AI = aromatase inhibitor; CBR = clinical benefit rate; CR = complete response; DOR = duration of response; ET = 
endocrine therapy; ICR = independent central review; ORR = objective response rate; OS = overall survival; PFS = progression-free 
survival; PR: partial response; QoL = quality of life 
